The pharmacokinetics and pharmacodynamics of drugs are different in adult and paediatric
populations, the latter being particularly heterogeneous. These differences in …

Opinion statement Bone tumors, particularly osteosarcomas and members of the Ewing
Sarcoma Family of Tumors (ESFT), are typical malignancies of adolescents and young …

Acute kidney injury due to high‐dose methotrexate (HDMTX) is a serious, life‐threatening
toxicity that can occur in pediatric and adult patients. Glucarpidase is a treatment approved …

BACKGROUND: Osteosarcoma is the most common malignant bone tumor in children and
young people. Efficacy of multiagent MAP (methotrexate, doxorubicin [Adriamycin], cisplatin) …

Growing evidence suggests that polymorphisms of genes coding for transporters or
enzymes may partially explain the large between subject variability reported for …

The aim of this study is to promote a model based on the fractional differential calculus
related to the pharmacokinetic individualization of high dose methotrexate treatment in …

Purpose The objectives of this study were to characterize the population pharmacokinetics
of MTX in patients with acute lymphoblastic leukemia (ALL) with ages ranging from 2 to 16 …

Preoperative high-dose methotrexate (HD-MTX) with folinic acid (leucovorin) rescue is still a
mainstay in the treatment of osteosarcoma. This anticancer agent is characterized by a …

Background Aims of this study were the validation of C-MYC involvement in methotrexate
(MTX) resistance and the assessment of clinical impact of C-MYC and dihydrofolate …

Methotrexate, when used in high doses (12 g/m 2) in the treatment of osteosarcoma, shows
wide between-subject variability (BSV) in its pharmacokinetics. High-dose methotrexate is …